Neonc Technologies Holdings (NTHI) Interest & Investment Income (2024 - 2026)
Neonc Technologies Holdings (NTHI) posted quarterly Interest & Investment Income of $52319.0 for Q1 2026, up 1.2% year-over-year from $51699.0 in Q1 2025, and up 25421.46% quarter-over-quarter from $205.0 in Q4 2025.
Neonc Technologies Holdings (NTHI) Interest & Investment Income (2024 - 2026) Analysis & Trends
Neonc Technologies Holdings (NTHI) has reported Interest & Investment Income for 3 consecutive years, with $52319.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income rose 1.2% year-over-year to $52319.0; the TTM figure through Mar 2026 stood at $88064.0 (down 95.88% YoY), while the FY2025 annual figure was $6.9 million, up 186.16% from the prior year.
- Interest & Investment Income climbed to $52319.0 in Q1 2026 per NTHI's latest filing, from $205.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $2.1 million in Q2 2024 and bottomed at $205.0 in Q4 2025.
- Historically, Interest & Investment Income has averaged $278227.4 across 3 years, with a median of $20706.0 in 2024.
- Annual changes were most pronounced in 2025 — Interest & Investment Income sank 98.61% — and 2026, when it climbed 1.2%.
- Neonc Technologies Holdings' Interest & Investment Income stood at $3446.0 in 2024, then sank by 94.05% to $205.0 in 2025, then jumped by 25421.46% to $52319.0 in 2026.
- Business Quant data shows NTHI's Interest & Investment Income at $52319.0 in Q1 2026, $205.0 in Q4 2025, and $6815.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Neonc Technologies Holdings | 116.41 Mn | 116.41 Mn | - | 483,112.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 483,112.00 |
| Mar 31, 2026 | 52,319.00 |
| Dec 31, 2025 | 205.00 |
| Sep 30, 2025 | 6,815.00 |
| Jun 30, 2025 | 28,725.00 |
| Mar 31, 2025 | 51,699.00 |
| Dec 31, 2024 | 3,446.00 |
| Sep 30, 2024 | 12,687.00 |
| Jun 30, 2024 | 2.07 Mn |